Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19
Carolina García‐Vidal, Pedro Puerta‐Alcalde, Aina Mateu, Genoveva Cuesta, Fernanda Meira, Carlos Lopera, Patricia Monzó, Marta Santos Bravo, Gerard Dueñas, Mariana Chumbita, Nicole García-Pouton, Anna Gayà, Marta Bodro, Sabina Herrera, Mar Mosquera, Francesc Fernández‐Avilés, José Antonio Martínez, Josep Mensa, Eva Giné, María Ángeles Marcos, Àlex Soriano
Abstract
This work has been financed by funds for research ad hoc COVID-19 from citizens and organizations patronage to Hospital Clínic de Barcelona-Fundació Clínic per a la Recerca Biomèdica. This research forms part of an activity that has received funding from EIT Health. EIT Health is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union that receives support from the European Union´s Horizon 2020 Research and Innovation Program. PP-A [JR20/00012 and PI21/00498], NG-P [FI19/00133], and CG-V [PI21/01640] have received research grants funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. The funders had neither a specific role in study design or collection of data, nor in writing of the paper or decision to submit. CG-V has received honoraria for talks on behalf of Gilead Science, MSD, Novartis, Pfizer, Janssen, Lilly as well as a grant from Gilead Science and MSD. AS has received honoraria for talks on behalf of Merck Sharp and Dohme, Pfizer, Novartis, Angellini, as well as grant support from Pfizer. PC has received honoraria for talks on behalf of Merck Sharp and Dohme, Pfizer, Gilead and Alexion. JM has received honoraria for talks on behalf of Merck Sharp and Dohme, Pfizer, Novartis and Angellini. PP-A has received honoraria for talks on behalf of Merck Sharp and Dohme, Lilly, ViiV Healthcare and Gilead Science.